Off‐label use of Dupilumab for the treatment of moderate to severe Atopic Dermatitis in children below 6 years old: A case series

2021 ◽  
Author(s):  
J. Da ◽  
K. Ali ◽  
K. Lu ◽  
H. Lou ◽  
Y. Qiu ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Case Series ◽  
Severe Atopic Dermatitis ◽  
Off Label Use ◽  
Off Label ◽  
Label Use

scholarly journals Off label use of lithium in the treatment of Huntington′s disease: A case series

2013 ◽  
Vol 55 (1) ◽  
pp. 81 ◽  
Author(s):  
Vijay Danivas ◽  
NagarajS Moily ◽  
Rohini Thimmaiah ◽  
Kesavan Muralidharan ◽  
Meera Purushotham ◽  
...  
Keyword(s):  
Case Series ◽  
Off Label Use ◽  
Off Label ◽  
Label Use

scholarly journals «Off-label» use of botulinic toxin type A preparations in neurological practice

2018 ◽  
Vol 20 (2) ◽  
pp. 195-201
Author(s):  
L R Akhmadeeva ◽  
Kh P Derevyanko
Keyword(s):  
Botulinum Toxin ◽  
Therapeutic Option ◽  
Botulinum Toxin Type A ◽  
Case Series ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Off Label Use ◽  
Off Label ◽  
Positive Effects ◽  
Label Use

The modern view on the application of botulinum toxin type A for the off-label use in neurology and foreign experience analysis are presented. The «off-label» category referred to any prescription of a medication in case of using it for unregistered indications, with product instruction violation or in the presence of contraindications including age restrictions. The sources of information about medicines were the leaflets of manufacturers of medicines and the State Register of Medicines. It is well known that Botulinum toxin type A is a good therapeutic option for treating children with cerebral palsy. Increased efficacy of regularly repeated cycles with Onabotulinumtoxin A in medication-overuse headache patients beyond the first year of treatment. Botulinum toxin type A is effective in the management of sialorrhea. Botulinum toxin type A is a safe and effective treatment for primary axillary hyperhidrosis and produces high levels of patient satisfaction. Facing depression with botulinum toxin: positive effects on mood have been observed in subjects who underwent treatment of glabellar frown lines with botulinum toxin and, in an open case series, depression remitted or improved after such a treatment. Botox injection significantly improved foot dystonia, pain and lower limb functional outcomes in patients with Parkinson’s disease with deep brain stimulation. The paper describes the problems associated with the lack of clinical data about the possibility of using botulinum toxin type A in different conditions, emphasizes the need to organize clinical trials and educational programs for neurologists as well as more active implementation of protocols for the treatment of patients.

DI-051 Tolvaptan off-label use in hyponatraemia due to heart failure. A case series

2016 ◽  
Vol 23 (Suppl 1) ◽  
pp. A140.1-A140
Author(s):  
M Vázquez-Real ◽  
U Baños Roldán ◽  
A Mesa-Jiménez ◽  
C Donoso Rengifo ◽  
M Murillo Izquierdo
Keyword(s):  
Heart Failure ◽  
Case Series ◽  
Off Label Use ◽  
Off Label ◽  
Label Use

Off label use of PICC as umbilical arterial catheter: Clinical case series

2021 ◽  
pp. 112972982110080
Author(s):  
Barone Giovanni ◽  
Natile Miria ◽  
Ancora Gina
Keyword(s):  
Clinical Case ◽  
Blood Pressure Monitoring ◽  
Case Series ◽  
Arterial Catheter ◽  
Off Label Use ◽  
Off Label ◽  
Single Lumen ◽  
Umbilical Catheters ◽  
Umbilical Arterial Catheter ◽  
Label Use

Umbilical arterial catheters are often placed at birth in critical ill neonates. Advantages of umbilical arterial catheterization include continuous blood pressure monitoring, accurate blood gas and frequent blood samplings. We described the off-label use of a third generation polyurethane power injectable 3 Fr single lumen peripheral inserted central catheter as umbilical arterial catheter. This clinical case series opens new scenarios about the off-label use of power PICC in newborns. Prospective studies are needed to evaluate the safety and advantages of PICCs as umbilical catheters over the conventional old generation polyurethane neonatal catheters.

scholarly journals The off-label use of anakinra in pediatric systemic autoinflammatory diseases

2020 ◽  
Vol 12 ◽  
pp. 1759720X2095957
Author(s):  
Valerio Maniscalco ◽  
Sarah Abu-Rumeileh ◽  
Maria Vincenza Mastrolia ◽  
Edoardo Marrani ◽  
Ilaria Maccora ◽  
...  
Keyword(s):  
Inflammatory Diseases ◽  
Interleukin 1 ◽  
Systemic Juvenile Idiopathic Arthritis ◽  
Case Series ◽  
Autoinflammatory Diseases ◽  
Off Label Use ◽  
Off Label ◽  
Rheumatologic Diseases ◽  
Valuable Treatment ◽  
Label Use

Interleukin 1 (IL-1), a central mediator of innate immunity, is considered a master cytokine of local and systemic inflammation. IL-1 has emerged as pivotal in the pathogenesis of autoinflammatory diseases (AIDs), and blockade of its pathway has become a crucial target for therapy. Anakinra (ANA), a recombinant IL-1β receptor antagonist, was the first anti-IL-1 agent employed in clinical practice. ANA is currently approved for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, adult-onset Still’s disease, and cryopyrin-associated autoinflammatory syndrome. It has also been successfully used for off-label treatment of various monogenic, polygenic, or undefined etiology systemic AIDs. This review describes currently available evidence for the off-label use of ANA in pediatric rheumatologic diseases. Specifically, the use of ANA in Kawasaki disease, idiopathic recurrent pericarditis, Behçet disease, monogenic AIDs, undifferentiated AIDs, chronic non-bacterial osteomyelitis, macrophage activation syndrome, and febrile infection-related epilepsy, in terms of its safety and efficacy. In selected pediatric rheumatic disorders, the off-label administration of ANA appears to be effective and safe. In order to control severe and/or relapsing disease, ANA should be considered as a valuable treatment option in children suffering from rare inflammatory diseases. However, currently available data consist of retrospective studies and short case series; thus, randomized controlled trials and larger series with long-term follow up are mandatory to better assess the efficacy and cost effectiveness of ANA in these challenging patients.

Off-Label Use of Sirolimus and Everolimus in a Pediatric Center: A Case Series and Review of the Literature

2019 ◽  
Vol 21 (3) ◽  
pp. 185-193 ◽  
Author(s):  
M. Bevacqua ◽  
F. Baldo ◽  
S. Pastore ◽  
E. Valencic ◽  
Alberto Tommasini ◽  
...  
Keyword(s):  
Case Series ◽  
Off Label Use ◽  
Review Of The Literature ◽  
Off Label ◽  
Pediatric Center ◽  
Label Use

Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective review

2020 ◽  
Vol 82 (2) ◽  
pp. 407-411 ◽  
Author(s):  
Sean Igelman ◽  
Anastasia O. Kurta ◽  
Umar Sheikh ◽  
Ashley McWilliams ◽  
Eric Armbrecht ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Retrospective Review ◽  
Pediatric Patients ◽  
Off Label Use ◽  
Off Label ◽  
Multicenter Retrospective Review ◽  
Label Use
Sign in / Sign up

Export Citation Format

Share Document